3-hydroxy-N-(3-hydroxybenzyl)benzamide | 148234-81-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-hydroxy-N-(3-hydroxybenzyl)benzamide
• 英文别名: N-(3-hydroxybenzyl)-3-hydroxybenzamide；3-hydroxy-N-[(3-hydroxyphenyl)methyl]benzamide
• CAS: 148234-81-5
• 化学式: C₁₄H₁₃NO₃
• 分子量: 243.262
• InChiKey: OWJFWXNNZVUCNB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(氨甲基)苯酚 、 间羟基苯甲酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 二氯甲烷 为溶剂， 以32 %的产率得到3-hydroxy-N-(3-hydroxybenzyl)benzamide
  参考文献：
  名称：

  Hydroxybenzamide derivatives protect pancreatic β cell by suppressing unfolded protein response activation

  摘要：

  AbstractEndoplasmic reticulum (ER) stress‐induced Pancreatic β‐cell dysfunction and death plays important roles in the development of diabetes. The 1,2,3‐triazole derivative 1 is one of only a few structures that have thus far been identified that protect β cells against ER stress, but it is limited for its narrow activity range. In this study, we designed and synthesized a series of hydroxybenzamide (HBA) derivatives in which the triazole pharmacophore was substituted with an amide linker. Structure–activity relationship studies identified WO3i (3‐hydroxy‐N‐(4‐[trifluoromethyl]benzyl)benzamide) that possesses β‐cell protective activity against ER stress at a 100% maximal activity with EC50 at 0.19 μM). We showed that WO3i suppresses the expression of CHOP, a key mediator of ER stress‐induced apoptosis, and the activation of apoptotic genes. Mechanistically, we further showed that WO3i suppresses the ER stress‐induced activation of all three pathways of unfolded protein response—ATF6, IRE1α, and PERK. Identification of this novel β‐cell‐protective scaffold thus provides a new promising modality for the potential for drug development for the treatment of diabetes.

  DOI：

  10.1111/cbdd.14093

文献信息

• PHELLODENDRINE ANALOGS AND ALLERGY TYPE IV SUPPRESSOR CONTAINING THE SAME AS ACTIVE INGREDIENT
  申请人：TSUMURA & CO.

  公开号：EP0613879A1

  公开（公告）日：1994-09-07

  Phellodendrine analogs represented by general formula (I), wherein A represents the group (a); B represents hydrogen, lower alkyl or lower acyl, or alternatively A and B together with the adjacent nitrogen atom form a substituted 1,2,3,4-tetrahydroisoquinoline ring represented by general formula (II), R₁₁, R₁₂, R₂₁, R₂₂, R₃₁ and R₃₂ represent each hydrogen, hydroxyl or lower alkoxy; n₁ represents a number of 0 to 2; n₂ represents a number of 1 and 2; and m₁ represents a number of 0 to 1, provided tsat when A represents the group (b), and n₂ is 2, B is lower acyl, and that when A and B together form a substituted 1,2,3,4-tetrahydroisoquinoline ring, n₁ is 1 and m₁ is not 0. These analogs (I) and related compounds have an excellent activity of suppressing allergy type IV and hence are utilizable as a medicine efficacious against diseases wherein allergy type IV participates, such as chronic hepatitis, intractable asthma, nephrotic syndrome or rheumatism.

  通式(I)代表的黄柏碱类似物，其中 A 代表基团(a)；B 代表氢、低级烷基或低级酰基，或者 A 和 B 与相邻的氮原子一起形成取代的 1,2,3,4-四氢异喹啉环、R₁₁、R₁₂、R₂₁、R₂₂、R₃₁ 和 R₃₂ 分别代表氢、羟基或低级烷氧基；n₁ 代表 0 至 2；n₂ 代表 1 和 2；m₁ 代表 0 至 1，条件是当 A 代表基团(b)，且 n₂ 为 2 时，B 为低级酰基，且当 A 和 B 共同形成取代的 1，2，3，4-四氢异喹啉环时，n₁ 为 1，m₁ 不是 0。这些类似物（I）和相关化合物具有抑制 IV 型过敏的优异活性，因此可用作对 IV 型过敏参与的疾病（如慢性肝炎、难治性哮喘、肾病综合征或风湿病）有效的药物。